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Abstract 
Background: We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group 
A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, 
group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional 
surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant 
chemotherapy. Herein we report the results of this group B.
Methods: Twenty patients with high-grade, locally advanced and deep STS located in lower extremities (n = 12), 
upper extremities (5) or trunk wall (3) were included. The median age was 59 years and 14 patients were males. The 
treatment regimen consisted of 6 cycles of doxorubicin (60 mg/m2) and ifosfamide (6 g/m2), with three cycles given 
neoadjuvantly, and preoperative radiotherapy (1, 8 Gyx2/daily to 36 Gy) between cycles 2 and 3. After a repeated MRI 
surgery was then conducted, and the remaining 3 chemotherapy cycles were given postoperatively at 3 weeks inter-
vals. Survival data, local control, toxicity of chemotherapy and postoperative complications are presented.
Results: Median follow-up time for metastasis-free survival (MFS) was 2.8 years (range 0.3–10.4). The 5-year MFS was 
49.5% (95% confidence interval [CI] 31.7–77.4). The median follow-up time was 5.4 years (range 0.3–10.4) for overall 
survival (OS). The 5-year OS was 64.0% (95% CI 45.8–89.4). The median tumour size was 13 cm, with undifferentiated 
pleomorphic sarcoma (n = 10) and synovial sarcoma (n = 6) diagnosed most frequently. All patients completed sur-
gery. Resection margins were R0 in 19 patients and R1 in 1 patient. No patients had evidence of disease progression 
preoperatively. Three patients experienced a local recurrence, in 2 after lung metastases had already been diagnosed. 
Eleven patients (55%) had postoperative wound problems (temporary in 8 and persistent in 3).
Conclusions: Preoperative chemotherapy and radiotherapy were associated with temporary wound-healing prob-
lems. Survival outcomes, local control and toxicities were deemed satisfactory when considering the locally advanced 
sarcoma disease status at primary diagnosis.
Trial registration This study was registered at ClinicalTrials.gov Identifier NCT00790244 and with European Union Drug 
Regulating Authorities Clinical Trials No. EUDRACT 2007-001152-39
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Background
Preoperative chemotherapy (CT) and radiotherapy (RT) 
have previously been studied as an integrated treatment 
plan for patients with primary soft tissue sarcomas (STS) 
[1, 2]. Several potential benefits of preoperative chemo-/
radiotherapy have been suggested, including an ability to 
assess primary tumour response to a given chemothera-
peutic regimen and to facilitate radical surgical removal, 
as well as to initiate earlier systemic treatment to combat 
subclinical metastatic disease. In a recent study the Ital-
ian and Spanish Sarcoma Groups have shown, such com-
bined treatment is feasible and safe with limited increase 
in wound complications [3].
According to formal guidelines [4], doxorubicin and 
ifosfamide are still not regarded as standard treatment 
in patients with high-grade localised soft-tissue sarcoma, 
neither as adjuvant nor neoadjuvant chemotherapy, 
despite a demonstrated benefit in several studies [5–10]. 
Our prospective, non-randomised Scandinavian Sarcoma 
Group (SSG) clinical study, SSG XX, was also designed 
to investigate the combination of adjuvant doxorubicin 
and ifosfamide in high risk STS [11]. In group A planned 
for primary surgery, accelerated radiotherapy was sched-
uled postoperatively between cycles 3 and 4 with a 5-year 
metastasis-free survival of 70.4% and overall survival 
76.1% [11]. The increasing evidence for the benefit of 
adjuvant RT [12, 13] led to the introduction of an acceler-
ated RT administered between courses of chemotherapy 
in SSG’s former protocol SSG XIII [14] and pursued also 
in SSG XX [11]. The SSG XX protocol had a separate 
treatment arm (group B) devoted to patients with locally 
advanced STS considered to have a high risk for intral-
esional surgery. These patients were given both pre- and 
postoperative chemotherapy, as well as accelerated RT 
before surgery. Here we report our experiences regarding 
the feasibility and outcomes of this combination.
Methods
Criteria for inclusion
The main eligibility criteria for SSG XX, group B were 
age ≥ 18 to ≤ 75  years, WHO performance status ≤  1, 
and a locally advanced primary STS of high-grade histol-
ogy (Grade III or IV in a 4 graded scale) located in the 
extremities or trunk wall. Only patients with a tumour of 
anatomical location and/or extension implying an obvi-
ous risk for intralesional margins were eligible. Tumour 
size was defined as the longest diameter on MRI at diag-
nosis. Tumour depth was defined in relation to the deep 
fascia. The patients were treated at four sarcoma centres 
in Sweden and two in Norway. Most cases were discussed 
at a surgical sarcoma network, a SSG web-based forum 
established to evaluate the risk for intralesional surgery 
and the need for preoperative treatment.
A core-needle biopsy or an open surgical biopsy was 
performed for classification of tumour type, grading of 
malignancy and histological diagnosis provided by the 
local pathologist. Diagnosis based on fine needle cytol-
ogy alone was not accepted. The SSG Pathology Refer-
ence Group later reviewed the morphology in all cases 
according to the WHO-classification and malignancy 
grade, applying the Broders’ system [15–17]. Distinct 
grading may be unreliable in core-needle biopsies, and 
the pathologists considered the best assessment to be low 
grade and high grade, recognising that high grade will 
encompass both Broders’ grade 3 and 4. A core needle 
biopsy does not allow definition of the histological risk 
factors (vascular invasion, infiltrative growth, necrosis) as 
used in SSGXX, group A [11].
The following histiotypes were not eligible: extraskel-
etal osteosarcoma or chondrosarcoma, Ewing sarcoma, 
rhabdomyosarcoma, Kaposi sarcoma, clear cell sarcoma, 
alveolar soft part sarcoma, epithelioid sarcoma and radia-
tion induced sarcoma.
Mandatory investigations at screening, during treat-
ment and at follow-up visits have previously been pre-
sented [11]. The complete SSG XX protocol is available 
on the SSG website [18].
Treatment
An outline of the treatment, involving scheduling of 
MRI, CT, RT and surgery, is presented in Fig. 1. A maxi-
mum of 28  days was allowed from diagnostic biopsy to 
start of chemotherapy. Doxorubicin 60 mg/m2 and ifos-
famide 6  g/m2 were given with a 3  weeks interval for 
patients < 70  years of age and with doses of 50/5 from 
age ≥ 70  years. Details of CT and use of granulocyte 
colony-stimulating factor (G-CSF) have previously been 
published [11].
Accelerated RT allowing shortened treatment time was 
interposed from week 4 to 6, after completion of the two 
initial CT cycles and before the 3rd cycle (Fig.  1). This 
scheduling allowed the maintenance of a high overall 
dose intensity of the CT given. The fractionation sched-
ule was 1.8 Gy twice daily to 36 Gy, with at least 6 h inter-
val between the two daily fractions and 5 treatment days 
per week. Due to a radiosensitising effect of doxorubicin, 
the minimal interval between doxorubicin (cycle 2) and 
RT was set to 7 days. Clinical target volume (CTV) was 
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defined by adding a 2 cm margin in all directions to the 
gross tumour volume (GTV), based on the baseline MRI 
examination. The choice of the conformal radiation treat-
ment technique was decided by each centre.
Surgery was planned 3–4 weeks after RT to minimise 
the fibrotic tissue response. A preoperative MRI was 
repeated to document any changes in tumour size and 
extension. Two weeks after surgery, the first of the three 
remaining cycles of chemotherapy was given (Fig. 1).
All patients underwent surgery at a sarcoma centre. At 
that time, their neutrophil levels should be ≥ 1.0 × 109/l 
and thrombocytes ≥  80 × 109/l. The classification of mar-
gins, according to the SSG guidelines [18], was coopera-
tively determined by the surgeons and pathologists at 
each sarcoma center.
Details of RT for SSG XX groups A and B combined 
will be published later, with emphasis on quality assess-
ment of the radiation dose distributions and target vol-
ume definitions in correlation with local recurrences, as 
well as formal scoring of late effects.
End‑points
The primary end-point was metastasis-free survival 
(MFS), calculated from the date of CT 1 (first chemo-
therapy cycle) until the first of the events of metastasis 
or death from any cause. Overall survival (OS) was a 
secondary endpoint defined as the time from CT 1 until 
death from any cause.
The secondary endpoints also included local recur-
rence, defined as the time from the date of CT 1 to local 
recurrence (with death considered a competing event) 
and the proportion of patients with progression of local 
disease preoperatively. Lastly, surgical margin status 
scored as wide, marginal and intralesional, as well as R0, 
R1 and R2 status, are also reported.
Statistical analyses
Descriptive analyses were used. Treatment endpoints, as 
well as toxicity from CT and RT, were analysed in all 20 
patients who started chemotherapy.
The survival analyses were based on follow-up data 
up to 2  years after the last patient enrolment (which 
occurred on June 30, 2014), at which time the data-
base was locked according to the a priori analysis plan. 
Patients with no events were censored either at the last 
date of follow-up or at the predefined date of data lock 
(June 30, 2016).
A final survival analysis, with use of follow-up data 
until December 31, 2019, is also presented.
The Kaplan–Meier method was used to estimate MFS 
and OS [19]. For the analyses of MFS, patients who were 
alive and disease free were censored at the date of the 
last follow-up, but not later than December 31, 2019. For 
the analyses of OS, data for patients who were alive were 
censored at the date of last follow-up, but not later than 
December 31, 2019. Cox regression analyses to study rel-
ative risks were not performed due to the low number of 
patients.
The dose intensity of CT was calculated using the 
method reported in previous studies [11, 14, 20].
Results
Patients
The patient demographics, tumour characteristics and 
histological subtypes are shown in Table  1. The timing 
of various treatments completed by individual patients 
is shown by case numbers in Fig. 2. Inclusion of patients 
(n = 20) in this group with preoperative treatment (group 
B of SSG XX) was closed in June 2014, when the planned 
number of patients in the postoperative and adjuvant 
group A (n = 160) had been fully recruited [11].
Nineteen patients had limb-sparing primary surgery; 
only in one patient was an amputation deemed necessary 
(case 8). Hence, the latter patient was not evaluable for 
scoring of any wound complications related to RT. This 
patient had a synovial sarcoma (13  cm) located in the 
distal forearm, with close relation to vessels and nerves, 
but after 3 CT cycles and RT, the tumour was unchanged 
(MRI). He therefore underwent amputation 4 weeks later, 
distal to the elbow, with a 5  cm proximal margin from 
the tumour followed by the 3 remaining CT cycles. He 
RT 36 Gy MR I Surgery
CT1 CT2 (1.8 x 2/d x 10d) CT3 CT4 CT5 CT6
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
weeks
Fig. 1 Treatment schedule. Chemotherapy (CT): ≥ 18 and < 70 years of age: Day 1: doxorubicin 60 mg/m2, 4-h infusion (IV); Day 1, 2 and 3: 
ifosfamide 2 g/m2/day as 2-h infusion, dose per cycle 6 g/m2 [with an equal dose of 2-mercaptoethane sulphonate sodium (MESNA)]. ≥ 70 
and ≤ 75 years: doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 (given as above). Granulocyte colony-stimulating factor was given routinely after each 
cycle
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developed a solitary pulmonary metastasis (45 mm) that 
was surgically removed 3.5 years later and is NED as of 
his last follow-up after 8 years.
Importantly, none of the 20 patients experienced local 
tumour progression preoperatively.
Resection margins were wide (R0 resection) in 13 
patients, marginal (R0) in 6 patients (cases 1, 5, 9, 12, 13 
and 16) and intralesional (R1) in 1 (case 2).
Metastases‑free and overall survival
The analysis according to the described statistical plan in 
the protocol was done based on the data collected up to a 
time point exactly 2 years after complete enrolment in the 
SSG XX trial. By that definition, the data cut-off became 
June 30, 2016. Later events were therefore not included 
in this first analysis. As stated above, we also decided to 
make a later analysis for group B (not done for group A) 
since several years had elapsed. This analysis included all 
data up to December 31, 2019. Survival curves for these 
late analyses only are shown (Figs. 3, 4).
Median follow-up of patients in the pre-planned analy-
ses of the primary end-point MFS was 2.1  years (range 
0.3–10.4). The estimated MFS rate at 5 years was 44.0% 
(95% CI 24.4–79.5). For overall survival (OS), the median 
Table 1 Patients demographic and  tumor characteristics 
of eligible patients
Characteristics Numbers







 Lower extremity (including gluteal and groin) 12
 Upper (including shoulder) 5








 Undifferentiated pleomorphic sarcoma 10
 Pleomorphic liposarcoma 1
 Leiomyosarcoma 1
 Synovial sarcoma 6
 Malignant peripheral nerve sheath tumor 1
 Myxofibrosarcoma 1
Fig. 2 SSG XX, group B, time schedule for chemotherapy, 
radiotherapy and surgery
Fig. 3 Metastases-free survival (Kaplan–Meier Curve; % with 95% 
CI = confidence interval) of 20 patients with high risk soft tissue 
sarcoma and a median follow-up 2.8 years
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follow-up time was 3.1 years (range 0.3–10.4). The 5-year 
estimated OS was 66.7% (95% CI 47.7–93.2).
As of the end of 2019, distant metastases had occurred 
in 10 patients (50%), 9 to the lung (cases 2, 7, 8, 9, 10, 11, 
14, 15 and 16) and one to the cerebrum (case 17). Nine 
patients had died (45%), all from sarcoma metastases. 
The median follow-up of patients in this analysis of MFS 
was 2.8 years (range 0.3–10.4). The final estimated MFS 
rate at 5 years was 49.5% (95% CI 31.7–77.4) (Fig. 3). For 
overall survival (OS), the median follow-up time was 
5.4 years (range 0.3–10.4). The final estimated 5-year OS 
was 64% (95% CI 45.8–89.4) (Fig. 4).
Chemotherapy cycles and dose intensity
Sixteen patients received all the planned 6 cycles, 1 
patient had 5 cycles, 2 patients 3 cycles and 1 patient had 
2 cycles only (Fig. 2). Median dose intensity for doxoru-
bicin and ifosfamide combined was only 79.0% (range 
33–86).
For logistical reasons two patients had 3 cycles of CT 
before RT and three patients received 4 cycles before 
surgery (Fig. 2). One patient who had surgery after only 
2 cycles of CT and RT did not have more CT due to a 
non-healing surgical wound complication (case 15). She 
later died of metastases. Two patients who had 3 preop-
erative cycles did not receive postoperative treatment. In 
one this was due to cerebral metastases diagnosed shortly 
after surgery with rapid clinical deterioration and death 
(case 17), and in the other due to refusal of postoperative 
CT (case 19).
Only 3 patients had their first postoperative cycle as 
scheduled within 15 days postoperatively (cases 5, 8 and 
14); 10 patients had this cycle between day 15 and 23, 3 
patients between day 28 and 34 (cases 3, 10 and 20) and 1 
patient at day 68 (case 13).
Chemotherapy toxicity
The CT toxicity was recorded according to Common Ter-
minology for Adverse Events (CTCAE), version 3.0. In 
general, CT was well tolerated and no worse than in our 
earlier described larger SSG XX group of patients who 
only underwent postoperative CT and RT [11]. Table  2 
presents all toxicities reported in more than one patient 
and numbers that had grade 3–4 toxicity. Neutropenia, 
without fever and thrombocytopenia, was the most com-
mon side effect. One case of pulmonary embolism grade 
4 was reported as the most serious toxicity. No fatal tox-
icities occurred.
Long-term cardiac and renal toxicities were measured 
by left ventricular ejection fraction (LVEF) and glomer-
ular filtration rate (GFR), respectively, at several time 
points during and after the treatment. The last measure-
ments were scheduled, according to the SSG XX proto-
col, at 10 years after end of treatment. The majority of the 
patients did not show any late cardiac or renal effects, but 
several data points were missing (i.e. the investigations 
were not performed). Some patients also had very few, if 
any, measurements because of rapid disease progression 
dismissing the study-related follow-up. Among the 15 
and 16 patients who had at least one measurement of car-
diac and renal toxicity, respectively, four patients showed 
a grade 1 cardiac toxicity and just one had grade 1 renal 
toxicity.
Radiotherapy and toxicity
Eighteen patients received the scheduled RT to 36  Gy 
preoperatively after 2 cycles without any delays (Fig.  2). 
Acute RT toxicity was recorded at each chemotherapy 
Fig. 4 Overall survival (Kaplan–Meier Curve; % with 95% 
CI = confidence interval) of 20 patients with high risk soft tissue 
sarcoma and a median follow-up 5.4 years
Table 2 Toxicity according to CTCAE score
a All grades of toxicities occurring in > 1 patient or any grade 3–4
b Number of patients with CTCAE toxicities grade 3–4
Toxicity All  gradesa Grade 3–4b
Number of patients Number of patients
Neutropenia without fever 17 12
Neutropenia with fever 3 3
Thrombocytopenia 16 6
Anaemia 3 3
Wound infection 2 2




ALAT increased 6 0
Creatinine increased 2 0
Fever, unspecified 2 0
Pulmonary embolism 1 1
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cycle until 6  weeks after last cycle. The RTOG Acute 
Radiation Toxicity Scoring was used [21].
Maximum skin toxicity due to RT during the treat-
ment period was grade 4 in 1 patient (5%), grade 3 in 4 
patients (20%), grade 2 in 6 patients (30%) and grade 1 in 
5 patients (25%). Scoring 0 was reported for 4 patients. In 
2 patients only, toxicity resulted in a delay of CT. Notably, 
very few patients had late radiotoxicity.
None of the patients developed a second cancer.
Local recurrence rate
Three patients developed a local recurrence (LR). This 
related to one patient with wide margin by primary sur-
gery of a tumour (12  cm, UPS) in lower extremity that 
developed LR 5.5  years after primary surgery (5.8  years 
after cycle 1) and was salvaged by an uncomplicated re-
operation. The patient was NED at follow-up 3  months 
later (case 3). Furthermore, two patients, both having 
10 cm tumours (synovial sarcoma) in the lower extremi-
ties had LR 18  months after primary surgery (20 and 
21  months after cycle 1, respectively). The margins at 
primary surgery were wide (R0) and intralesional (R1), 
respectively. Interestingly, both these patients experi-
enced LR after first being diagnoses with pulmonary 
metastases (11 months and 4 months, respectively). Both 
died later of metastases (cases 2 and 11).
Surgical complications
No wound healing complications were observed in 
8 patients. Delayed wound healing in ranges of 2 to 
4 months occurred in 7 patients (cases 9, 11, 12, 13, 14, 
19 and 20) and lasting as long as 6 months in 1 patient 
(case 5). These patients all had early postoperative infec-
tions that were treated with antibiotics and wound 
revisions followed by vacuum pump treatment. One 
patient needed a skin transplant and healing occurred 
at 6 months (case 5). Three patients (cases 6, 15 and 17) 
had persistent wounds that did not heal, and two of them 
died early due to metastatic disease (cases 15 and 17). 
The third patient (case 6) was NED at last follow-up in 
2019 but with a still unresolved non-healing wound after 
multiple revisions and hyperbaric oxygen treatment.
Discussion
This study explored the possible benefit of combining 
neoadjuvant CT and preoperative, accelerated RT in a 
defined cohort of patients with high-grade STS, where 
an adequate surgical margin of primary surgery could 
not a priori be achieved (SSG XX, group B). Interest-
ingly, the surgical margins were in fact intralesional (R1) 
in only one patient. This regimen may thus be warranted 
for large extremity localised STS and proximally located 
tumours in the lower extremity/groin, when preservation 
of function is the goal and the tumour is located near 
critical structures, such as larger vessels and nerves. The 
local control rate was deemed satisfactory, as only 3 of 
the 20 patients experienced a local recurrence and in 
two this occurred after diagnosis of metastatic disease. 
Nine patients developed pulmonary metastases. Only 
one patient underwent a complete metastasectomy, with 
NED observed after 8  years. The 5-year estimated MFS 
and OS rates were 49.5% and 64.0%, respectively.
The Italian and Spanish Sarcoma Groups (ISG/GEIS) 
administered neoadjuvant and adjuvant CT with doxoru-
bicin and ifosfamide to similar patients. They concluded 
that CT may be omitted after 3 preoperative cycles, 
based on their study comparing treatment with 3 pre-
operative cycles only with that of addition of two further 
postoperative cycles [9]. The 10-year overall survival for 
both treatment arms was about 60% [22]. Interestingly, 
our survival data seems to be in accordance with the ISG/
GEIS trial. In the same study, preoperative RT (44–50 Gy) 
was given to 169 patients (from a total of 303 patients) 
and wound complications occurred in 13.5% [3]. Gron-
chi et al. showed in a recent publication that disease free 
and overall survival by histiotype-tailored neoadjuvant 
chemotherapy was not superior to anthracycline and 
ifosfamide in high-grade STS [23]. Their conclusion was 
that doxorubicin and ifosfamide should remain the regi-
men to choose whenever neoadjuvant chemotherapy (or 
adjuvant) is used.
As already mentioned, the addition of preoperative RT 
to CT is adopted at many centres as part of a multimodal 
treatment plan for patients with primary STS [1, 2, 10, 
24]. We did not include specific assessment of response 
into the protocol, neither by radiology nor pathology 
[18]. It was, however, mandatory to repeat MRI before 
surgery (after 3 preoperative cycles + radiotherapy), but 
in the clinical report forms only preoperative tumour 
progression was registered. Interestingly, no patients had 
preoperative tumour progression after a composite radi-
ological/clinical evaluation at the local hospital. Further-
more R0 resection margin was obtained in 19 patients (of 
20) which for all practical reasons is an important result, 
since all eligible patients in SSG XX, group B should have 
an obvious risk for intralesional surgery. In the ISG/GEIS 
study reported above, some cases had positive micro-
scopic margins, despite preoperative CT and RT, but 
this was not associated with an increased risk of distant 
spread or local recurrence [25].
Several studies have demonstrated no difference in the 
rates of local tumour control between pre-and postop-
erative RT [26–29]. The optimal timing of RT is debated 
and depends on factors such as tumour location and 
patient characteristics [30]. In patients where no preop-
erative RT has been given, the current consensus is that 
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postoperative RT is indicated in all high-grade STS fol-
lowing marginal and intralesional margin surgery, as 
well as after wide and marginal margin surgery in deep-
seated, high-grade tumours [4].
The value of preoperative RT for improving survival 
of patients with STS remains unproven [27]. O`Sullivan 
et al. [26] randomised 94 patients to preoperative (50 Gy, 
25 fractions) or postoperative (66  Gy, 33 fractions) RT 
and showed a slightly better overall survival in the preop-
erative group after a median follow-up time of 3.3 years. 
However, this benefit was lost after 5 years of follow-up 
(recurrence-free survival: 58% versus 59%) [31]. The tim-
ing of RT did not affect local control, but more patients 
had wound complications in the preoperative RT group 
than in the postoperative group [26]. Other researchers 
have also reported increased risk of wound complications 
[1, 32]. Nevertheless, preoperative RT is preferred by 
many due to its more favourable long-term risk profile, 
with less fibrosis, joint stiffness and oedema [31, 33, 34]. 
The temporary nature of wound complications also moti-
vates preoperative RT [30].
In the recently reported phase 3 study by ISG/GEIS, 
where preoperative RT was combined with doxorubicin 
and ifosfamide (3 cycles), the incidence of wound com-
plications was 17% whereas it was 10% with neoadju-
vant CT, alone or combined with postoperative RT [3]. 
In our present study, 11 of 20 patients had wound com-
plications, but these were mostly of short duration. Pos-
sibly, our 3 additional cycles postoperatively might have 
increased the toxicity. One factor to be kept in mind is 
that the acute toxicity profile associated with preopera-
tive RT may be mitigated by experienced surgeons using 
techniques such as free and pedicle flaps for high-risk 
locations. Therefore, these patients should be referred to 
specialised centres [25, 35]. All patients in our study were 
treated by experienced sarcoma surgeons.
For preoperative RT a dose of 50  Gy in 1.8–2  Gy in 
once-daily fractions over 5–6 weeks is the usual delivery 
schedule [4, 35]. Accelerated RT (36  Gy, 20 fractions of 
1.8 Gy per fraction, twice daily, 5 days per week) is equiv-
alent to a total dose of about 50 Gy [18]. The accelerated 
RT interposed between CT cycles was used in SSG`s for-
mer adjuvant protocol, SSG XIII [14] and subsequently 
in SSG XX where higher CT doses were given (group A) 
[11]. Acceptable treatment-related morbidity was dem-
onstrated [11, 14]. In the current study we evaluated 
accelerated RT in a preoperative setting in highly selected 
patients (group B). Accelerated radiotherapy interposed 
between CT cycles may allow the maintenance of a high 
overall dose intensity of the CT given as evident for both 
group A [11] and group B.
In a retrospective study, 89 patients with localised high 
risk STS had six courses of doxorubicin (50 mg/m2) and 
ifosfamide (5  g/m2) and hyperfractionated radiotherapy 
(1.5  Gy twice daily/ 42–60  Gy), given as preoperative 
treatment in 45 patients and as postoperative treatment 
in 44 patients [36]. In that study, the treatment-related 
complication rate was moderate, with a 5-year MFS of 
48% and a local control rate of 81%. The doses of CT and 
the dose per fraction of RT were lower than in our SSG 
XX study [11]. In the retrospective study reported [36] 
and in the previous SSG XIII study [14], it was shown 
that a low CT dose intensity had a negative impact on 
both metastasis-free and overall survival. For inadequate 
surgical margins, the hyperfractionated RT was given as 
a split-course procedure [36]. Their relatively high local 
recurrence rate might underscore the findings of Jebsen 
et al. [14], who showed that split-course RT to a greater 
total radiation dose could not compensate for poor surgi-
cal margins.
More recently, Spalec et  al. showed in a prospective 
study of 30 patients with borderline resectable STS that 
radiotherapy with 5 fractions of 5 Gy combined with pre-
operative chemotherapy was feasible [37]. R0 resection 
margin was obtained in 15 of the 23 patients and R1 in 
7 patients who had limb-sparing surgery. By pathological 
evaluation of the removed tumours < 50% stainable cells 
was found in 14 patients. Good early tolerance of the 
treatment was reported.
The non-randomised design and the low sample num-
ber in our study limit the interpretation of the results. 
The study strengths were the prospective design and the 
strict high risk inclusion criteria. We believe that our 
findings may add valuable information for clinical teams 
treating this particular and challenging group of STS 
patients.
Conclusions
A low local recurrence rate (3 of 20 patients) with an 
acceptable 5-year estimated MFS (49.5%) and OS (64.0%) 
rate were demonstrated in a very high risk group of STS 
patients (SSG XX, group B). Only one patient required 
an amputation. A combined preoperative CT and RT 
approach resulted in almost all operations rendering 
adequate surgical margins. Wound healing problems 
occurred in several patients but were mostly of a tempo-
rary nature. From these results we recommend preopera-
tive chemotherapy and radiotherapy to be considered for 
selected high risk patients after careful evaluation by a 
multidisciplinary team. Referral of STS patients to spe-
cialised centres is always recommended, and this is par-
ticularly important in high-grade locally advanced cases.
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